Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study
Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine.
“These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies,” said Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study’s senior authors. “Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer.”
Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy. Without a successful bone marrow transplant, few have any hope of long-term survival.
In the current study, 16 patients with relapsed B-ALL were given an infusion of their own genetically modified immune cells, called T cells. The cells were “reeducated” to recognize and destroy cancer cells that contain the protein CD19. While the overall complete response rate for all patients was 88 percent, even those with detectable disease prior to treatment had a complete response rate of 78 percent, far exceeding the complete response rate of salvage chemotherapy alone.
Dennis J. Billy, C.Ss.R, of Wynnewood, Pennsylvania, was one of the first patients to receive this treatment more than two years ago. He was able to successfully undergo a bone marrow transplant and has been cancer-free and back at work teaching theology since 2011. Paolo Cavalli, a restaurant owner from Oxford, Connecticut, remains in complete remission eight months after receiving his personalized T cell treatment.
A History of Scientific Achievements for Cell-Based Therapies
Cell-based, targeted immunotherapy is a new approach to treating cancer that harnesses the body’s own immune system to attack and kill cancerous cells. Unlike with a common virus such as the flu, our immune system does not recognize cancer cells as foreign and is therefore at a disadvantage in eradicating the disease. For more than a decade, researchers at Memorial Sloan Kettering have been exploring ways to reengineer the body’s own T cells to recognize and attack cancer. In 2003, they were the first to report that T cells engineered to recognize the protein CD19, which is found on B cells, could be used to treat B cell cancers in mice.
“Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients,” said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study’s senior authors. “It’s extremely gratifying to witness the astonishing results firsthand in my patients, having worked for more than a decade developing this technology from the ground up.”
In March 2013, the same team of researchers first reported the results of five patients with advanced B-ALL who were treated with cell therapy. Remarkably, all five patients achieved complete remissions.
Results Demonstrate Potential of New Therapy
In the current study, seven of the 16 patients (44 percent) were able to successfully undergo bone marrow transplantation — the standard of care and the only curative option for B-ALL patients — following treatment. Three patients were ineligible due to failure to achieve a complete remission, three were ineligible due to preexisting medical conditions, two declined, and one is still being evaluated for a potential bone marrow transplant. Historically, only 5 percent of patients with relapsed B-ALL have been able to transition to bone marrow transplantation.
The Latest on: Cell therapy
via Google News
The Latest on: Cell therapy
- Computational biology algorithm could help optimize culture conditions required for cell therapyon October 12, 2020 at 4:14 pm
Cellular therapy is a powerful strategy to produce patient-specific, personalised cells to treat many diseases, including heart disease and neurological disorders.
- SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&Don October 12, 2020 at 2:48 pm
SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell shares to the public ...
- Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwanon October 12, 2020 at 1:15 pm
Axis Therapeutics Limited, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell ...
- Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicineon October 12, 2020 at 8:09 am
Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced the publication in Nature Medici ...
- Therapy using immune system cells preserves vision in mice implanted with rare eye canceron October 12, 2020 at 8:04 am
A treatment that uses immune system T cells, combined with an immune-boosting drug packaged in an injectable gel, was found to preserve the vision of mice implanted with tissue from a human eye cancer ...
- Cell therapy Market Expected to Reach $48,115.40 Million by 2027—Allied Market Researchon October 12, 2020 at 6:06 am
According to a new report published by Allied Market Research, titled, “Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, End User, and Region: Opportunity Analysis and Industry ...
- Cell Therapy Market to Reach $48.11 Bn, Globally, by 2027 at 25.6% CAGR: Allied Market Researchon October 12, 2020 at 6:00 am
Allied Market Research published a report, titled, "Cell Therapy Market" by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type ...
- Computational approach shows promise for optimising culture conditions required for cell therapyon October 12, 2020 at 5:09 am
Cellular therapy is a powerful strategy to produce patient-specific, personalized cells to treat many diseases, including heart disease and neurological disorders. But a major challenge for cell ...
- Cell and Gene Therapy Tools, and Reagents Market 2020 Global Analysis, Opportunities And Forecast To 2025on October 12, 2020 at 4:52 am
Wiseguyreports.Com Adds “Cell and Gene Therapy Tools, and Reagents -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database The global market for ...
- Global Stem Cell Therapy Marketon October 10, 2020 at 2:22 am
“Global Stem Cell Therapy Market–Industry Trends and Forecast to 2027” focuses on the major drivers and restraints for the key players. These research report also provides Comprehensive analysis of ...
via Bing News